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The purpose of this viewpoint is to discuss the molecular design principles that guide 
development of synthetic antimicrobial polymers, especially those intended to mimic the 
structure of host defense peptides (HDPs). In particular, we focus on the principle of 
“amphiphilic balance” as it relates to some recently developed polyphosphoniums with somewhat 
atypical structure. We find that the fundamental concept of amphiphilic balance is still applicable 
to these new polymers, but that the method to achieve such balance is somewhat unique. We then 
briefly outline the future challenges and opportunities in this field. 
In the recent paper "Surprising Antibacterial Activity and Selectivity of Hydrophilic 
Polyphosphoniums Featuring Sugar and Hydroxyl Substituents",
[1]
 a set of novel 
polyphosponium-based polymers with alkyl, hydroxyl and sugar substituents was presented. This 
is a set of macromolecules that was synthesized through a new chemical approach and 
complements the existing classes of antimicrobial polymers. In particular, the mannose epitopes 
incorporated into these polymers for potential biorecognition via protein-carbohydrate 
interactions provides them with molecular features that could enable a different interaction 
mechanism for polymer-bacterial interaction compared to conventional polycationic 
antimicrobial polymers. Moreover, this library of phosphonium polymers yielded one member 
with very high antibacterial potency combined with very little toxicity to human red blood cells, 
and thus with very high selectivity: the hallmark of host defense peptide (HDP) and HDP mimics 
efficacy. This structure is a promising candidate for further study. Upon reflection, we felt the 
need to offer some additional discussion regarding the nature of the so-called “amphiphilic 
balance” design principle and how it might be applied to the structures in this recent paper. 
In numerous studies over the past few decades, several groups have established the 
relationships between the structure and activity of antimicrobial polymers.
[2]
 Universally, it has 
been found that some “balance” of hydrophobicity and cationic charge is an essential ingredient 
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for optimization of antimicrobial activity combined with low toxicity to human cells.
[3]
 Many 
efforts have been directed towards mimicking the structures and activities of HDPs, which are 
composed of various sequences of amino acids that incorporate cationic, hydrophobic, and 
neutral hydrophilic pendant groups. It has been proposed from a mechanistic standpoint that 
HDPs first bind to the bacterial cell membrane via electrostatic attraction between their cationic 
residues and the anionic lipid headgroups, followed by insertion of their hydrophobic residues 
into the non-polar membrane core, resulting in membrane permeabilization.
[4]
 Cationic and 
hydrophobic synthetic polymers behave in much the same manner. While neutral, hydrophilic 
residues (e.g. PEG, zwitterions, hydroxyls, and sugars) have been incorporated to fine-tune the 
amphiphilic balance to reduce toxicity, most antimicrobial polymers to date have involved 
hydrophobic alkyl chains, either directly conjugated to cationic centers or randomly alternating 
with cationic pendant groups (Figure 1a). This is particularly true of antimicrobial phosphonium 
polymers. Many structural variants have been investigated including different alkyl chains 
conjugated to phosphonium centers, different lengths of spacers to the polymer backbone, and 
different backbones.
[5]
 These studies demonstrated structure-dependent antimicrobial activity.
[5]
 
In this context, the potent antibacterial activity of HydroxyP
P
, a tris(hydroxypropyl)phosphinum-
functionalized polystyrene derivative containing hydrophilic pendant groups, was not predicted a 
priori but rather it was originally intended as a negative control sample. The excellent 
hemocompatibility of this polymer was also serendipitous, as it was not the product of targeted 
structure-based design. That being said, these serendipitous results do not overturn the idea of 
amphiphilic balance as a molecular design principle. 
 
Recently, a number of examples of active antibacterial polymers that do not contain linear 
alkyl side chains have been reported. For example, Gellman and coworkers were able to obtain 
good antibacterial activity and low hemolytic activity towards red blood cells using cyclic alkyl 
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groups as the hydrophobic residues on a polyamide backbone.
[6]
 Haldar similarly showed that 
cyclization and unsaturation of the hydrophobic groups in amphiphilic polymers are important 
determinants of bioactivity.
[7]
 Removing pendant hydrophobic groups altogether, Lienkamp and 
coworkers recently reported polyoxanorbornenes with pendant zwitterionic groups where the 
backbone imparted hydrophobicity instead.
[8]
 Similarly, Palermo and coworkers reported self-
immolative poly(benzyl ether)s with pendant oligo(ethylene glycol) and thioether-linked primary 





, while these polymers do lack pendant linear alkyl side chains, they do not lack 
amphiphilicity. Thus, we do not want the final sentence of reference [1]: “This intriguing result 
challenges the hydrophilic/lipophilic balance previously thought to be required for antibacterial 
activity.” to be misinterpreted. Indeed, all of the above molecules exhibit amphiphilicity. For 
example, as noted in reference [1] the hydrophobic polystyrene backbone and even the terminal 
reversible addition-fragmentation chain transfer (RAFT) group impart amphiphilicity to 
HydroxyP
P
. Thus, we wish to emphasize that the observations described in reference [1], and 
other recent examples, do not require us to abandon the idea of amphiphilic balance altogether. 
Rather, we think it is important to highlight that amphiphilic balance is not restricted to linear 
alkyl side chains as the source of hydrophobicity. 
Previous polyphosphoniums reported by Endo and coworkers featured long, linear alkyl side 
chains that increased the hydrophobicity of the polymer chains to such an extent that the 
polymers indiscriminately lysed biomembranes by a surfactant-like mode of biocidal action. By 
replacing the hydrophobic alkyl chains with neutral, modestly hydrophilic –(CH2)3OH groups, we 
believe that the overall hydrophobicity has been dialed down to enable cell-type selectivity. In 
other words, a combination of cationic and neutral, hydrophilic groups provided the requisite 
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“balance” to counter the very hydrophobic polymer backbones. In HydroxyP
P
, this balance just 
so happens to provide high antibacterial activity and low haemolytic activity.  
 
  
Figure 1. The broad diversity of polymer structures that employ a balance of hydrophobic, cationic, and 
neutral/hydrophilic groups to optimize biological activity. The image was reproduced, in part, from reference [3]. 
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At this stage, the mechanism of action of HydroxyP
P
 has not yet been investigated. As 
suggested in reference [1], it is possible that HydroxyP
P
 acts by membrane disruption, or by an 
alternative mechanism. This can only be resolved through future experiments. For example, it 
will be important to quantify the hydrophobicity of the polymer directly using measurements 
such as HPLC retention times
[10]
 and water-octanol partition coefficients,
[2q, 9a]
 to probe the 
mechanism through experiments such as dye leakage from liposomes
[2l, 2q-t, 2w, 10-11]
 and through 
electron microscopy.
[12]
 It is possible that HydroxyP
P
 will turn out to be amphiphilic and 
membrane disrupting, in line with the other selective antimicrobial polymers. It will also be 
interesting to tune further the structural features of HydroxyP
P
 including its backbone and 
substituents to understand and optimize its activity.  
As the field of antimicrobial polymers continues to expand, there are many key challenges 
and opportunities to deepen our understanding of structure-activity relationships as well as the 
mechanism(s) of action.  In terms of structural optimization of polymer chains, increasingly 
precise control of comonomer sequence, chain length distributions, tacticity, and chain 
architecture are currently considered high value targets (Figure 2). Molecules with new structural 
features are being introduced with the aim of 
affording both high antibacterial activity and 
selectivity, a key challenge in this field.  
While HydroxyP
P
 incorporates novel 
structural features, it is nevertheless possible 
that it acts by a membrane-disruption 
mechanism with selectivity afforded through 
its optimal hydrophilic-hydrophobic balance. 
Figure 2. Precision control of polymer synthesis for next-
generation antimicrobial polymers. 
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Whether new classes of cationic antimicrobial polymers that act by alternative mechanisms can 
or have been developed remains an open question. 
Growing concerns over the increasing emergence of antibiotic-resistant bacterial strains, 
combined with new synthetic polymer techniques, have led to a surge of recent interest in 
antibacterial polymers. Since the discovery of HDPs over 30 years ago, antimicrobial peptides 
and their synthetic mimics are just beginning to show promise in clinical trials. For example, the 
AMP-mimetic oligomer Brilacidin,
[13]
 developed by Polymedix and later acquired by Cellceutix, 
has successfully completed a phase 2b clinical trial for skin infections, showing efficacy similar 
to daptomycin. It is also in phase 2 trials for oral mucositis. Considering that Brilacidin was 
specifically designed and synthesized to mimic the cationic and hydrophobic properties of HDPs, 
the clinical success provides strong motivation for further development in this field. Once AMP-
mimetic polymer structures have been optimized for activity in vitro, it is crucial to translate 
prime candidates to in vivo studies that include biodistribution, pharamacokinetics and 
pharamacodynamics (PK/PD), as well as any side effects. Although the drug development 
process is exceedingly difficult, the benefits of a hit are potentially enormous. We look forward 
to witnessing the continued development of these vital polymers, ranging from the fundamentals 
of design and synthesis, to structure-activity relationships, mechanism of action, development of 
in vivo models, and ultimately clinical application. 
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